Loss of Treatment Benefit Due to Low Compliance with Bisphosphonate Therapy

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2007 Sep 18

PMID 17874028

Citations 55

Authors

F J A Penning-van Beest

J A Erkens

M Olson

R M C Herings

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Among 8,822 new female bisphosphonate users, non-compliant bisphosphonate use was associated with a 45% increased risk of osteoporotic fracture compared to compliant use (MPR >or=80%). Classifying compliance into five categories, fracture risk gradually increased with poorer compliance. These results emphasize the importance of treatment compliance in obtaining maximal treatment benefit.

Introduction: Bisphosphonates are widely used to treat osteoporosis and reduce fracture risk. Low compliance is frequent and will limit treatment benefit.

Methods: New female users of alendronate or risedronate between 1999-2004, aged >or=45 years were identified from PHARMO-RLS, including drug-dispensing and hospitalization data of >or= 2 million residents of the Netherlands. Patients were followed until first hospitalisation for an osteoporotic fracture, death, or end of study period. Compliance with bisphosphonates during follow-up was measured over 90-day intervals using Medication Possession Ratio (MPR). The association between compliance and fracture risk was analyzed using time-dependent Cox-regression.

Results: The study cohort included 8,822 new female bisphosphonate users, contributing in total 22,484 person-years of follow-up. During follow-up, 176 osteoporotic fractures occurred (excluding the first six months). Non-compliant bisphosphonate use was associated with a 45% increased fracture risk compared to compliant use (MPR >or= 80%). Classifying compliance into five categories, fracture risk gradually increased with poorer compliance (p-value <0.05 for trend). A MPR <20% was associated with an 80% increased fracture risk compared to a MPR >or= 90%.

Conclusions: These results show a statistically significant association between level of compliance with bisphosphonates and level of fracture risk, emphasizing the importance of treatment compliance in obtaining maximal treatment benefit.

Citing Articles

Total knee arthroplasty and periprosthetic distal femoral fracture: looking beyond the osteoporosis to previous osteoporotic fracture.

Park Y, Kim M, Nam H, Jeon J, Ha C Osteoporos Int. 2024; 35(8):1469-1475.

PMID: 38801524 DOI: 10.1007/s00198-024-07138-w.

Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.

Tsai Y, Wu C, Li C, Shih C, Chang Y, Hwang J Osteoporos Int. 2023; 34(10):1783-1791.

PMID: 37466659 DOI: 10.1007/s00198-023-06845-0.

Impact of the COVID-19 Pandemic on Adherence to Denosumab Therapy: A Single Center Study.

Kobayashi K, Sato K, Ando T, Ando K, Imura S Asian Spine J. 2023; 17(5):842-850.

PMID: 37408487 PMC: 10622821. DOI: 10.31616/asj.2022.0417.

Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: A propensity score matching analysis.

Kim S, Chung Y, Lee Y Osteoporos Sarcopenia. 2022; 8(3):98-105.

PMID: 36268493 PMC: 9577186. DOI: 10.1016/j.afos.2022.05.004.

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.

Nakamura Y, Shimizu T, Asano T, Shimodan S, Ishizu H, Takahashi D J Bone Miner Metab. 2021; 39(5):824-832.

PMID: 33821302 PMC: 8021003. DOI: 10.1007/s00774-021-01221-6.

References

McCombs J, Thiebaud P, McLaughlin-Miley C, Shi J . Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004; 48(3):271-87. DOI: 10.1016/j.maturitas.2004.02.005. View

Schlienger R, Kraenzlin M, Jick S, Meier C . Use of beta-blockers and risk of fractures. JAMA. 2004; 292(11):1326-32. DOI: 10.1001/jama.292.11.1326. View

Herings R, Stricker B, de Boer A, Bakker A, Sturmans F . Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med. 1995; 155(16):1801-7. View

Herings R, Stricker B, de Boer A, Bakker A, Sturmans F, Stergachis A . Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol. 1996; 49(1):115-9. DOI: 10.1016/0895-4356(95)00552-8. View

Johnell O, Kanis J, Oden A, Johansson H, De Laet C, Delmas P . Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005; 20(7):1185-94. DOI: 10.1359/JBMR.050304. View

Recker R, Gallagher R, MacCosbe P . Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005; 80(7):856-61. DOI: 10.4065/80.7.856. View

Cramer J, Amonkar M, Hebborn A, Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005; 21(9):1453-60. DOI: 10.1185/030079905X61875. View

Solomon D, Avorn J, Katz J, Finkelstein J, Arnold M, Polinski J . Compliance with osteoporosis medications. Arch Intern Med. 2005; 165(20):2414-9. DOI: 10.1001/archinte.165.20.2414. View

Penning-van Beest F, Goettsch W, Erkens J, Herings R . Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006; 28(2):236-42. DOI: 10.1016/j.clinthera.2006.01.002. View

10.

Lo J, Pressman A, Omar M, Ettinger B . Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006; 17(6):922-8. DOI: 10.1007/s00198-006-0085-2. View

11.

Huybrechts K, Ishak K, Caro J . Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2005; 38(6):922-8. DOI: 10.1016/j.bone.2005.10.022. View

12.

Siris E, Harris S, Rosen C, Barr C, Arvesen J, Abbott T . Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81(8):1013-22. DOI: 10.4065/81.8.1013. View

13.

van den Boogaard C, Breekveldt-Postma N, Borggreve S, Goettsch W, Herings R . Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin. 2006; 22(9):1757-64. DOI: 10.1185/030079906X132370. View

14.

Weycker D, Macarios D, Edelsberg J, Oster G . Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2006; 18(3):271-7. DOI: 10.1007/s00198-006-0230-y. View

15.

Gold D, Martin B, Frytak J, Amonkar M, Cosman F . A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin. 2007; 23(3):585-94. DOI: 10.1185/030079906X167615. View

16.

Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V . Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005; 21(12):1895-903. DOI: 10.1185/030079905X74862. View

17.

. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285(6):785-95. DOI: 10.1001/jama.285.6.785. View

18.

McClung M . Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother. 2001; 1(2):225-38. DOI: 10.1517/14656566.1.2.225. View

19.

Pasco J, Kotowicz M, Henry M, Sanders K, Nicholson G . Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med. 2002; 162(5):537-40. DOI: 10.1001/archinte.162.5.537. View

20.

Cummings S, Melton L . Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359(9319):1761-7. DOI: 10.1016/S0140-6736(02)08657-9. View